Patients with gastrointestinal neuroendocrine tumors with carcinoid syndrome are more than twice as likely to have certain pre-existing diagnoses compared with patients without carcinoid syndrome, according to the results of a study.
Post-traumatic stress disorder may be persistent or worsening in patients with cancer up to 4 years after an initial diagnosis of the disorder, according to the results of a study.
A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I study presented at the ASH Annual Meeting.
About one-third of patients with previously treated chronic lymphocytic leukemia (CLL) were minimal residual disease negative after 6 months of treatment with the combination of targeted agents ibrutinib and venetoclax, according to the results of the TAP CLARITY study.
Patients with Hodgkin lymphoma treated with a drug combination including brentuximab vedotin achieved superior progression-free survival, with a reduction in the risk for progression, death, or need for additional anticancer therapy, compared with the standard four-drug chemotherapy regimen.
Hospice use occurred more frequently among Medicare beneficiaries with acute and chronic leukemias who were transfusion dependent, according to the results of a study presented at the ASH Annual Meeting.
After undergoing 5 years of adjuvant endocrine therapy, 2 years of extended anastrozole proved as effective as 5 years for preventing breast cancer recurrence among postmenopausal women with hormone receptor (HR)-positive breast cancer, according to the results of the ABCSG-16 phase III trial.
Disease-free survival after 9 weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to disease-free survival after 1 year of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer.
Undergoing acupuncture significantly reduced joint pain related to treatment with aromatase inhibitors in postmenopausal women with early-stage breast cancer.
Treatment with gonadotropin-releasing hormone analog can safely and effectively protect ovarian function and has the potential to preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.